Compare FBIO & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIO | MCN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Canada |
| Employees | 101 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 125.2M |
| IPO Year | N/A | N/A |
| Metric | FBIO | MCN |
|---|---|---|
| Price | $3.28 | $5.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 809.2K | 61.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | $49.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $5.16 |
| 52 Week High | $4.53 | $6.39 |
| Indicator | FBIO | MCN |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 37.73 |
| Support Level | $2.47 | $5.87 |
| Resistance Level | $3.96 | $6.18 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 21.12 | 7.41 |
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.